Cargando…
EZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cells
INTRODUCTION: Inflammatory breast cancer (IBC) is the most metastatic variant of breast cancer with the poorest survival in all types of breast cancer patients and presently therapeutic targets for IBC are very limited. Enhancer of zeste homolog 2 (EZH2) is frequently expressed in human IBC and its...
Autores principales: | Mu, Zhaomei, Li, Hua, Fernandez, Sandra V, Alpaugh, Katherine R, Zhang, Rugang, Cristofanilli, Massimo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3850122/ https://www.ncbi.nlm.nih.gov/pubmed/24294976 http://dx.doi.org/10.1186/1756-9966-32-70 |
Ejemplares similares
-
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
por: Mu, Zhaomei, et al.
Publicado: (2014) -
Mutational studies on single circulating tumor cells isolated from the blood of inflammatory breast cancer patients
por: Bingham, Catherine, et al.
Publicado: (2017) -
Inflammatory breast cancer (IBC): clues for targeted therapies
por: Fernandez, Sandra V., et al.
Publicado: (2013) -
Presence of anaplastic lymphoma kinase in inflammatory breast cancer
por: Robertson, Fredika M, et al.
Publicado: (2013) -
TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients
por: Fernandez, Sandra V, et al.
Publicado: (2014)